Grifols Launches a Drug for Immunodeficiencies in Spain

Grifols launches its drug, called Xembify, to treat primary and secondary immunodeficiencies in Spain. The country becomes the first nation in the European Union (EU) where the drug is available and already has health authorization from several European countries and the United Kingdom.

Primary immunodeficiencies affect one in 2,000 births. In the case of the secondary ones, it is expected that antibody deficiency may become thirty times more common than primary deficiencies. Among them, those produced in patients with multiple myeloma stand out, a type of cancer of which between 2,500 and 3,000 new cases are diagnosed each year in Spain.

Grifols also plans to launch Xembify in Australia in the second half of the year and continue to drive growth in the United States. In the US market, the drug has been available since 2019, having a good response in patients with these pathologies. In addition, the Spanish company is working on the treatment of patients with hypogammaglobulinemia and recurrent infections with this drug.

If you want to read more about Grifols and its newly launched drug against immunodeficiencies, download for free our companion app. The Born2INvest mobile app keeps its readers up to date with the most important business news of the day.

Grifols has been marketing this drug in the United States since 2019

Primary and secondary immunodeficiencies are rare diseases such as chronic inflammatory demyelinating polyneuropathy, Guillain Barré syndrome, Kawasaki disease, multifocal motor neuropathy, chronic immune thrombocytopenia, and myasthenia gravis which are treated with immunoglobulins.

Grifols is a publicly traded Catalan pharmaceutical company. The company’s activity is focused on the research, development, manufacturing, and marketing of plasma-derived products (blood products), intravenous therapy products, and diagnostic systems, among others. The Barcelona plasma production plant is located in the town of Parets del Vallès.

The pharmaceutical company lost €108 million in the first quarter of 2023 due to restructuring costs, according to the latest published economic results. Without taking into account the adjustment plan, the company’s profit would have been €25.7 million.

Revenues from the blood products company rose by 23.2% up to March, reaching €1.56 billion. The company’s gross operating profit (Ebitda) increased by 19%, to €298 million.

__

(Featured image by ncb80 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.